A Parkinson's disease trial roadmap proposed by the Michael J. Fox Foundation for Parkinson's Research and the Alpha-Synuclein Clinical Path Working Group, published in the Journal of Parkinson's Disease, detailed the full translational framework for trials and the limitations of the Parkinson's biomarker toolkit. The roadmap also recommends biomarker toolkit expansion for clinical outcome surveillance, but factors such as analytical biomarker assay validation and predictive value awareness based on the biomarker's intended utility should be considered before including biomarkers for decision-making, researchers said.
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.